Roschenko Valeri, Ayoub Abdallah M, Engelhardt Konrad, Schäfer Jens, Amin Muhammad Umair, Preis Eduard, Mandic Robert, Bakowsky Udo
Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany.
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Baldingerstraße, 35033 Marburg, Germany.
Pharmaceutics. 2023 Oct 2;15(10):2412. doi: 10.3390/pharmaceutics15102412.
Next to alcohol and tobacco abuse, infection with human papillomaviruses (HPVs) is a major risk factor for developing head and neck squamous cell carcinomas (HNSCCs), leading to 350,000 casualties worldwide each year. Limited therapy options and drug resistance raise the urge for alternative methods such as photodynamic therapy (PDT), a minimally invasive procedure used to treat HNSCC and other cancers. We prepared lipid-coated polymeric nanoparticles encapsulating curcumin as the photosensitizer (CUR-LCNPs). The prepared CUR-LCNPs were in the nanometer range (153.37 ± 1.58 nm) and showed an encapsulation efficiency of 92.69 ± 0.03%. Proper lipid coating was visualized using atomic force microscopy (AFM). The CUR-LCNPs were tested in three HPV and three HPV HNSCC lines regarding their uptake capabilities and in vitro cell killing capacity, revealing a variable but highly significant tumor cell inhibiting effect in all tested HNSCC cell lines. No significant differences were detected between the HPV and HPV HNSCC groups (mean IC: (9.34 ± 4.73 µmol/L vs. 6.88 ± 1.03 µmol/L), suggesting CUR-LCNPs/PDT to be a promising therapeutic option for HNSCC patients independent of their HPV status.
除了酗酒和吸烟外，感染人乳头瘤病毒（HPV）是导致头颈部鳞状细胞癌（HNSCC）的主要风险因素，每年在全球造成35万人死亡。有限的治疗选择和耐药性促使人们寻求光动力疗法（PDT）等替代方法，这是一种用于治疗HNSCC和其他癌症的微创手术。我们制备了包裹姜黄素作为光敏剂的脂质包被聚合物纳米颗粒（CUR-LCNPs）。所制备的CUR-LCNPs粒径在纳米范围内（153.37±1.58 nm），包封率为92.69±0.03%。使用原子力显微镜（AFM）观察到了合适的脂质包被。对三种HPV和三种HPV-HNSCC细胞系测试了CUR-LCNPs的摄取能力和体外细胞杀伤能力，结果显示在所有测试的HNSCC细胞系中均有不同但非常显著的肿瘤细胞抑制作用。HPV组和HPV-HNSCC组之间未检测到显著差异（平均IC：（9.34±4.73 μmol/L对6.88±1.03 μmol/L），这表明CUR-LCNPs/PDT对于HNSCC患者来说是一种有前景的治疗选择，与他们的HPV状态无关。
